Fore Biotherapeutics, a biotech company developing novel cancer therapies, announced today that it has appointed Bill Hinshaw as its new Chief Executive Officer and Board member, effective immediately.

Mr. Hinshaw succeeds Dr. Shawn M. Leland, who served as Advisor and Interim CEO during the transition period and will continue to support the company as a Board member.

Mr. Hinshaw is a seasoned leader in the biopharma industry, with over 30 years of experience in both large and emerging companies. He was previously the President, CEO and Board member of Axcella Therapeutics, a clinical-stage company developing therapies for complex diseases. Before that, he led the U.S. Oncology business of Novartis, overseeing a portfolio of blockbuster drugs and pipeline candidates. He also held various global leadership roles at Novartis and Schering Plough Corporation. He holds a B.S. in Molecular Biology from the University of Wisconsin.

Dieter Weinand, the Chairman of the Board of Directors, said: “We are thrilled to welcome Bill as our next CEO. He brings highly relevant experience to grow and scale Fore given his track record in both large and emerging life sciences companies. He is the right leader for this stage of our company’s journey and the Board and I are delighted to partner with Bill to navigate Fore’s path to continued success.”

Mr. Hinshaw said: “I am privileged and excited to lead Fore and work alongside the talented and committed team and build upon what has been accomplished to date. Fore is poised to develop targeted treatments that can have a transformational impact on the lives of patients suffering from cancer.”